Allianz Asset Management
BHVN

Allianz Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Allianz Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-183,768
Closed -$27.8M – 2076
2022
Q3 		$27.8M Sell
183,768
-51,300
-22% -$7.6M 0.06% 351
2022
Q2 		$34.3M Buy
235,068
+162,825
+225% +$20.8M 0.03% 513
2022
Q1 		$8.57M Buy
72,243
+10
+0% +$1.25K 0.01% 1035
2021
Q4 		$9.96M Sell
72,233
-17,117
-19% -$2.18M 0.01% 995
2021
Q3 		$12.4M Buy
89,350
+41,748
+88% +$5.21M 0.01% 922
2021
Q2 		$4.62M Buy
47,602
+16,663
+54% +$1.35M ﹤0.01% 1154
2021
Q1 		$2.11M Buy
30,939
+6,977
+29% +$564K ﹤0.01% 1383
2020
Q4 		$2.05M Buy
+23,962
New +$2.03M ﹤0.01% 1308
2020
Q1 		– Sell
-8,820
Closed -$481K – 2869
2019
Q4 		$481K Sell
8,820
-5,064
-36% -$251K ﹤0.01% 2443
2019
Q3 		$579K Sell
13,884
-58,230
-81% -$2.46M ﹤0.01% 2321
2019
Q2 		$3.16M Buy
72,114
+11,560
+19% +$652K ﹤0.01% 1702
2019
Q1 		$3.12M Sell
60,554
-469
-0.8% -$20.3K ﹤0.01% 1665
2018
Q4 		$2.26M Buy
+61,023
New +$2.2M ﹤0.01% 1727

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Allianz Asset Management's BHVN Position: Q4 2022 in Review

Allianz Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 183,768 shares — an estimated $27.8M sold.

Allianz Asset Management first reported a position in BHVN in Q4 2018 and held it in 13 quarters. The position peaked at $34.3M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Allianz Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Allianz Asset Management sold 183,768 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $27.8M.
  • Allianz Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and held it in 13 quarters.
  • Allianz Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $34.3M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Allianz Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.